India to China: Dapagliflozin Export Trade Route

The India to China Dapagliflozin corridor is one of India's established pharmaceutical export routes, with 61 shipments documented worth a combined $2.8M USD. The route is dominated by CIPLA LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's dapagliflozin manufacturing sector.

Across 4 active suppliers, the average shipment value stands at $45.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with dapagliflozin's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 26 days port-to-port. The route has recorded an annual growth rate of 25.5%, placing it at rank #15 among India's top dapagliflozin export destinations globally.

On the import side, key buyers of Indian dapagliflozin in China include SINO UNIVERSAL PHARMACEUTICAL CO, SINO UNIVERSAL PHARMACEUTICALCO LTD, SINO UNIVERSAL PHARMACEUTICAL CO. and 7 others. SINO UNIVERSAL PHARMACEUTICAL CO is the single largest importer with 19 shipments valued at $1.4M USD.

India's dapagliflozin exports to China are driven primarily by a handful of large-scale manufacturers. CIPLA LIMITED with 38 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 4 active exporters signals a competitive but concentrated market — buyers in China benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA LIMITED, CIPLA LIMITED , ALEMBIC PHARMACEUTICALS LIMITED — together account for 100% of total trade value on this route. The average shipment value of $45.2K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as dapaquis (dapagliflozin tablets 10mg)(30 tablets/bottle) (21021 packs x 1x30's=630630 nos) and dapaquis (dapagliflozin tablets 10mg)(30 tablets/bottle) (21004 packs x 1x30's=630120 nos), suggesting that buyers in China tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, SINO UNIVERSAL PHARMACEUTICAL CO is the largest importer with 19 shipments worth $1.4M USD — representing 52% of all dapagliflozin imports from India on this route. A total of 10 buyers are active on this corridor.